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Abstract In Huntington’s disease (HD) atrophy of the
caudate nucleus and putamen has been described many
years before clinical manifestation. Volume changes of the
pallidum, thalamus, brainstem, accumbens nucleus, hip-
pocampus, and amygdala are less well investigated, or
reported with contradicting results. The aim of our study is
to provide a more precise view of the speciﬁc atrophy of
the subcortical grey matter structures in different stages of
Huntington’s disease, and secondly to investigate how this
inﬂuences the clinical manifestations. All TRACK-HD
subjects underwent standardised T1-weighted 3T MRI
scans encompassing 123 manifest HD (stage 1, n = 77;
stage 2, n = 46), 120 premanifest HD (close to onset
n = 58, far from onset n = 62) and 123 controls. Using
FMRIB’s FIRST and SIENAX tools the accumbens
nucleus, amygdala, brainstem, caudate nucleus, hippo-
campus, pallidum, putamen, thalamus and whole brain
volume were extracted. Results showed that volumes of the
caudate nucleus and putamen were reduced in premanifest
HD far from predicted onset ([10.8 years). Atrophy of
accumbens nucleus and pallidum was apparent in pre-
manifest HD in the close to onset group (0–10.8 years). All
other structures were affected to some degree in the man-
ifest group, although brainstem, thalamus and amygdala
were relatively spared. The accumbens nucleus, putamen,
pallidum and hippocampus had a strong signiﬁcant corre-
lation with functional and motor scores. We conclude that
volume changes may be a sensitive and reliable measure
for early disease detection and in this way serve as a bio-
marker for Huntington’s disease. Besides the caudate
nucleus and putamen, the pallidum and the accumbens
nucleus show great potential in this respect.
Keywords Huntington’s disease   Volumetric MRI  
Accumbens nucleus   Pallidum   Biomarker
Introduction
Huntington’s disease (HD) is an autosomal, dominantly
inherited, slowly progressive, neurodegenerative disease
localised on chromosome four. The pathophysiological
mechanism is complex and although impaired energy
metabolism and neuronal excitotoxicity are named as
major contributors [9, 32], it is still not fully understood,
but the main result is neuronal dysfunction and loss in the
brain. The disease is characterised by clinical symptoms in
the motor, cognitive, and psychiatric domains.
Loss of brain cells and their connections, referred to as
atrophy, can be visualised with magnetic resonance imag-
ing (MRI) techniques and has been the focus of many
studies in search of objective biomarkers for tracking
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region of interest, due to previous ﬁndings in pathological
studies that demonstrated the most severe loss of neurons
in this region [28]. In manifest HD, the evidence for
widespread atrophy is extensive, whereby several MRI
studies showed striatal [4, 6, 8, 11, 13, 16, 20, 26, 34] and
cortical atrophy [29, 31]. The striatal atrophy occurs in the
premanifest stages of HD, with atrophy of the caudate
nucleus and putamen present up to a decade or more before
clinical manifestation [5, 7, 14, 17, 25, 40].
Other subcortical grey matter structures have been
examined to a lesser degree. Thalamic [6, 8, 13, 15] and
pallidum [2, 8, 30, 34] atrophy is apparent in the manifest
stages of HD; however, ﬁndings are controversial in the
premanifest stage, as not all studies are in agreement [7, 10,
14, 17, 30, 40]. Atrophy of the hippocampus, amygdala,
accumbens nucleus, and brainstem has only been reported
in the manifest stage in a very limited number of studies [8,
30]. Whole brain atrophy has been demonstrated in HD [12,
39]. However, the rate of volume reduction of the subcor-
tical structures as compared to whole brain atrophy has not
been reported in any of the above mentioned studies and is
of importance as this regional atrophy may very well only
be a reﬂection of whole brain atrophy. Correlation studies
have been performed for volume reductions and global
clinical measures in manifest HD [8, 20, 30]. However,
reports on the relationship of atrophy with clinical measures
of all these structures in different disease stages in one large
cohort has not been previously reported.
With the possibilities of new therapies for HD, there has
been increasing interest in the development of robust,
reproducible biomarkers to assess the efﬁcacy of potential
treatments. The TRACK-HD study is an international
multi-centre study investigating candidate biomarkers for
HD and encompasses a large, well deﬁned, sample of HD
gene carriers [39]. Application of a fully automated MRI-
analysis tool to this study sample provides the opportunity
to study brain atrophy in detail within a very large HD
cohort. The aim of this study is to provide a more precise
overview of the speciﬁc atrophy of the subcortical grey
matter structures in different disease stages, whilst taking
into account whole brain atrophy and provide better targets
for biomarker research. Secondly, we aim to examine the
relationship of all subcortical grey matter structure vol-
umes to clinical measures for HD.
Methods
Subjects
The TRACK-HD study recruited 366 participants from
four centres (The National Hospital for Neurology and
Neurosurgery in London, The Department of Medical
Genetics at University of British Columbia in Vancouver,
The Department of Genetics and Cytogenetics at the
Ho ˆpital de la Salpetrie `re-Universite ´ Pierre and Marie Curie
in Paris and the Department of Neurology at Leiden Uni-
versity Medical Center in Leiden), totalling 123 early
manifest HD, 120 premanifest HD and 123 control sub-
jects. Inclusion criteria for the early manifest HD group
consisted of genetic conﬁrmation of an expanded CAG
repeat of C40, presence of motor disturbances on the
Uniﬁed Huntington’s Disease Rating Scale (UHDRS),
deﬁned as a diagnostic motor conﬁdence score of 4 and a
total motor score (TMS) of [5, and a total functional
capacity (TFC) of C7. Inclusion criteria for the premanifest
group consisted of genetic conﬁrmation of an expanded
CAG repeat of C40, absence of motor disturbances on the
UHDRS, deﬁned as a TMS of B5. Furthermore, premani-
fest gene carriers required a burden of pathology score
[250 [27], based on CAG length and age, to ensure a
premanifest HD sample close to onset. Spouses or partners
of premanifest and affected subjects or gene-negative sib-
lings were recruited as healthy control subjects. The control
group was age- and gender-matched to the combined pre-
manifest and manifest HD group. Further subdivision of
the premanifest group was performed on the basis of pre-
dicted years to diagnosis into preHD-A (10.8 or more years
to disease onset) and preHD-B (closer than 10.8 years to
disease onset) based on Langbehn’s et al. survival analysis
formula [18, 19]. The early manifest HD subjects were also
divided into two groups based on disease stage by means of
TFC score, the HD1 group (TFC score 11–13) and the HD2
group (TFC score 7–10) [35]. The study was approved by
the local ethical committees and written informed consent
was obtained from each subject. For full details on study
design see [39].
Clinical measures
From the total TRACK-HD assessment battery, the
UHDRS motor scale and TFC were used for this study. The
UHDRS TMS is a representation of the severity of motor
disturbances, scores potentially range from 0 to 124, with
higher scores indicating more severe motor abnormalities.
The TFC is a scale used for assessment of global impair-
ments within daily activities, ranging from 0 to 13, with
lower scores indicating impaired global functioning.
MRI acquisition
All participants underwent 3 T MRI scanning. T1-weighted
image volumes were acquired using a 3D MPRAGE
acquisition sequence on a 3 T Siemens or a 3 T Phillips
whole body scanner with the following imaging parameters:
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123TR = 2200 ms (Siemens)/7.7 ms (Philips), TE = 2.2 ms
(Siemens)/3.5 ms (Philips), FA = 10 (Siemens)/8 (Phi-
lips), FOV = 28 cm (Siemens)/24 cm (Philips), matrix size
256 9 256 (Siemens)/224 9 224 (Philips), 208 (Siemens)/
164 (Philips), sagittal slices to cover the entire brain with a
slice thickness of 1.0 mm with no gap between slices.
Post-processing
All T1-weighed scans were analysed using software pro-
vided by FMRIB’s software library (FSL) [37]. Eight
subcortical regions were assessed using FMRIB’s inte-
grated registration and segmentation tool (FIRST) [21–23],
namely the accumbens nucleus, amygdala, brainstem,
caudate nucleus, hippocampus, pallidum, putamen, and the
thalamus. Total brain tissue volume was estimated with
SIENAX [36, 38]. For details on MRI post-processing,
please see the Supplementary data. The whole-brain vol-
ume was used to calculate ratios of atrophy of the sub-
cortical structures to whole-brain atrophy. The obtained
ratio was divided by the control group value in order to
obtain an easily interpretable ratio whereby 1.00 is the
control (normal) value ratio. The following formula was
used:
½volume structure= whole-brain volume ð
  volume structureÞ =control group value
A value below 1.00 demonstrates that the structure
displays more atrophy than the overall whole-brain
atrophy. A value greater than 1.00 demonstrates that the
overall whole-brain atrophy is greater than the atrophy of
the structure at hand.
Statistics
Analysis of variance for group comparison was performed
for volumes and ratios of the eight different subcortical
structures, whilst correcting for intracranial volume, study
site, age and gender. (Note that each site used a different
MRI scanner model, thus, potential scanner effects can not
be differentiated from site effects.) Comparisons of each
structure were made for each disease group as compared to
the control group, and as compared to the previous disease
stage group, e.g. the preHD-B group was, besides com-
parison to the control group, also compared to the preHD-A
group. We calculated partial correlations between the
various subcortical structures and total motor score and
total functional capacity from the UHDRS battery. These
correlations used volumes corrected for intracranial vol-
ume and were further controlled for age, site, and gender
by ‘‘partialling’’ these covariates out during the correlation
calculations. The UHDRS TMS and TFC analyses were
performed on the basis of a two-way group division,
namely the premanifest gene carriers and the manifest HD
group in order to keep sufﬁcient power to perform this
analysis. The signiﬁcance level was set at p value\0.05.
Results
Characteristics
The clinical characteristics of the ﬁve study groups are
shown (Table 1). The progressive nature of HD inherently
leads to a higher age of the manifest HD groups. Except for
the HD2 group, which displayed lower levels of education,
there were no signiﬁcant differences in education level
between the disease groups and the controls. For full details
on group characteristics we refer to the recent baseline
TRACK-HD paper [39].
Volumes
Examples of a typical output from the segmentation by the
FIRST and SIENAX tools are depicted (Fig. 1), for the
FIRST examples only the left hemisphere segmentations
are shown; however, both sides were segmented for the
analysis.
Volume comparisons for eight subcortical structures in
ﬁve groups are shown (Table 2). Furthermore, Fig. 2
shows the amount of volume reduction in terms of per-
centage of the control value. The putamen and the caudate
nucleus show a similar pattern of a smaller volume in the
preHD-A group and in every subsequent disease stage
group with a continuous decline in volume. The accumbens
nucleus and pallidum show a decreased volume in the
preHD-B group and from every following disease stage
group as compared to the controls as well as to the previous
disease stage group except for the accumbens nucleus
between HD1 and HD2.
The brainstem and thalamus show signs of reduced
volume in preHD-B, HD1 and HD2 as compared to the
control group.
The amygdala showed no reduced volume as compared
to the control group. The hippocampus showed volume
reduction in stages preHD-B, HD1 and HD2 as compared
to controls. In terms of percentages of volume reduction as
compared to the control group value it is apparent that the
pallidum and accumbens nucleus show marked atrophy
with only 62 and 60% of the normal volume remaining in
the HD2 group, respectively. These structures are closely
followed by the putamen and the caudate nucleus with 67
and 70% remaining volume, respectively. Percentages for
all structures in the four disease stages are also available in
the supplementary data.
414 J Neurol (2011) 258:412–420
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Comparisons for volume ratio of eight structures as com-
paredtowhole-brainatrophyareshown(Table 3).Asmaller
ratio indicates that the volume of this speciﬁc structure
declines faster than the overall brain atrophy (Table 4).
The putamen atrophy ratio showed a continuous smaller
value across subsequent disease stage groups. The caudate
nucleus atrophy ratio showed a similar pattern, except
within the manifest stage where this ratio did not show a
signiﬁcant difference across HD1 and HD2. The accum-
bens nucleus and the pallidum atrophy ratio showed a
decrease over disease stages from the preHD-B group
onwards.
The ratio of whole-brain atrophy to amygdala atrophy is
comparable or slightly higher to the control group ratio.
The atrophy ratio for the brainstem and thalamus shows no
or slightly higher ratios as compared to the control group,
stating that atrophy of these structures is comparable or
slower to whole brain atrophy. Finally, the hippocampus
atrophy ratio shows a drop in value in HD2 as compared to
control and HD1.
Clinical measures
The UHDRS TMS in the premanifest stage is most strongly
correlated to the atrophy of the caudate nucleus (r = 0.272,
p = 0.003) and putamen (r =- 0.240, p = 0.009), but
also to the atrophy of accumbens nucleus, pallidum and
thalamus. The TFC demonstrates a strong ceiling effect in
the premanifest stage and no signiﬁcant correlations are to
be found. In the manifest stage of the disease, the UHDRS
TMS is most strongly related to the putamen (r =- 0.530,
p\0.0001), pallidum (r =- 0.390, p\0.0001) and ac-
cumbens nucleus (r\-0.380, p\0.0001), but also to the
hippocampus, thalamus, and brainstem. The TFC is most
strongly correlated to atrophy of the putamen (r = 0.270,
p = 0.004), hippocampus (r = 0.240, p = 0.01) and pal-
lidum (r = 0.230, p = 0.01) and a weak correlation to
accumbens nucleus and brainstem.
Discussion
The aim of this study was to provide a comprehensive
overview of the atrophy of subcortical structures, with
respect to disease stage while taking into account whole-
brain atrophy. The main ﬁndings show that all subcortical
grey matter structures at some point have a reduced
absolute volume. However, the accumbens nucleus, the
caudate nucleus, the pallidum and the putamen display a
true progressive decline in volume reduction which is
disproportionate to overall whole-brain atrophy and this is
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123already visible in the premanifest stages of HD. Con-
versely, the amygdala, brainstem and thalamus do show
reduced volumes, but this merely reﬂects the overall
whole brain atrophy rate. The hippocampus is exceptional
in the fact that only in the manifest stage is a true rapid
decline in this structure observed. Furthermore, the vol-
ume reductions of the accumbens nucleus, putamen, pal-
lidum and hippocampus have a severe impact on clinical
measures in manifest HD.
The atrophy of the caudate nucleus and putamen in the
premanifest stages conﬁrms earlier studies. The fact that
this happens a decade or more before estimated time to
onset is in accordance with the ﬁndings of Aylward et al.
[3], the ﬁndings of the PREDICT-HD study [25] and with
the results reported in TRACK-HD baseline paper [39].
Atrophy of the pallidum and thalamus in the premanifest
stages of HD is controversial. Campodonico et al. and
Harris et al. report no signiﬁcant reduction in volume of the
Fig. 1 a Example
segmentations by FSL FIRST.
Dark blue Brainstem, Blue
Pallidum, Light blue Thalamus,
Green Caudate nucleus, Dark
red Accumbens nucleus, Red
Putamen, Copper Hippocampus,
Pink Amygdala. b Example
output from the FSL SIENAX
tool. Red color depicts the ﬁnal
sienax segmentation results
Table 2 Volumes
Control PreHD-A PreHD-B HD1 HD2
Mean volume SD Mean volume SD Mean volume SD Mean volume SD Mean volume SD
Accumbens 1,202 251 1,170 258 1,038**
 245 873**
 239 752** 239
Amygdala 3,345 825 3,331 939 3,346 869 3,246 757 2,914 851
Brainstem 24,043 2,672 23,828 3,001 23,011* 2,947 22,204* 2,592 21,098**
 3,083
Caudate 6,915 989 6,325** 1,067 5,722**
 923 5,057**
 756 4,830** 816
Hippocampus 8,417 1,271 8,391 1,319 8,115*
 1,290 7,668** 1,233 6,617**
 1,351
Pallidum 3,593 505 3,526 562 3,099**
 510 2,718**
 615 2,238**
 679
Putamen 10,277 1,383 9,610** 1,442 8,644**
 1,220 7,548**
 987 6,935**
 1,203
Thalamus 16,112 1,707 16,152 1,718 15,620** 1,656 14,525**
 1,524 13,681** 1,448
Volumetric analysis of eight structures. Means are the observed unadjusted measured values (mm
3). Signiﬁcance is after correction for ICV, site,
gender and age
* signiﬁcant difference from controls p\0.05
** signiﬁcant difference from controls p\0.001
 signiﬁcant difference from previous group p\0.05
 signiﬁcant difference from previous group p\0.01
416 J Neurol (2011) 258:412–420
123pallidum [7, 10], while others do report this ﬁnding [14, 17,
40]. With regard to the thalamus in the premanifest stage,
reports of reduced volume are available in favour [10, 40]
and in dispute [14, 24] of thalamic involvement. Our
ﬁndings, using 3 T MRI and in the largest cohort reported
thus far, conﬁrms that atrophy in the pallidum is apparent
in the premanifest stage closer to predicted disease onset,
but not in the further from predicted onset stage. Although
thalamic atrophy is also apparent in the premanifest close
to onset stage, this merely reﬂects the whole brain atrophy.
The brainstem, thalamus, and amygdala follow the
normal atrophy rate of the whole brain in the manifest
stages of the disease. In fact, in HD stage 1 the brainstem
Fig. 2 Percentage of volume reduction. Percentage of volume for
eight structures as compared to the control value
Table 3 Ratios
PreHD-A PreHD-B HD1 HD2
Ratio SD Ratio SD Ratio SD Ratio SD
Accumbens nucleus 1.00 0.18 0.91**
 0.18 0.82**
 0.18 0.73**
 0.18
Amygdala 0.97 0.26 1.03 0.23 1.06* 0.23 1.00* 0.29
Brainstem 0.99 0.07 0.99 0.08 1.04*
 0.10 1.00
 0.11
Caudate nucleus 0.92** 0.13 0.87**
 0.11 0.83**
 0.13 0.81** 0.14
Hippocampus 1.00 0.13 1.01 0.13 1.03 0.16 0.91**
 0.18
Pallidum 0.97 0.12 0.91**
 0.12 0.85**
 0.21 0.70**
 0.21
Putamen 0.93** 0.11 0.87**
 0.08 0.82**
 0.08 0.77**
 0.09
Thalamus 1.00 0.73 1.01 0.73 1.01 0.86 0.97 0.08
Ratio analysis of volumes for eight structures. Ratios are the observed unadjusted measured values(mm
3). Signiﬁcance is after correction for
ICV, site, gender and age
* p\0.05 from control group
** p\0.001 from control group
 p\0.05 from previous group
 p\0.001 from previous group
Table 4 Volume correlations with motor score and functional capacity
UDHRS Total motor score Total functional capacity
PreHD HD PreHD HD
Partial rp Partial rp Partial r p Partial r p
Accumbens nucleus -0.24 0.01 -0.38 \0.0001 -0.025 0.79 0.21 0.03
Amygdala -0.121 0.21 -0.11 0.23 -0.14 0.13 0.10 0.29
Brainstem -0.12 0.23 -0.22 0.02 0.00 [0.99 0.20 0.03
Caudate nucleus -0.272 0.003 -0.14 0.12 -0.15 0.10 0.02 0.82
Hippocampus 0.03 0.78 -0.31 0.0008 0.03 0.73 0.24 0.01
Pallidum -0.20 0.03 -0.39 \0.0001 0.03 0.75 0.23 0.01
Putamen -0.24 0.009 -0.53 \0.0001 0.00 0.99 0.27 0.004
Thalamus -0.23 0.015 -0.29 0.002 0.05 0.59 0.13 0.17
Statistic is partial correlation of volumes corrected for intracranial volume with statistical (partial) correction for site, gender and age
UHDRS Uniﬁed Huntington’s Disease Rating Scale, preHD premanifest Huntington’s disease, HD manifest Huntington’s disease
J Neurol (2011) 258:412–420 417
123and the amygdala show signs of being relatively spared.
The hippocampus shows a different pattern of atrophy as it
starts to show signs of atrophy in the preHD-B stage, but
really becomes signiﬁcant in terms of volume loss in HD
stage 2. To some degree the above described ﬁndings have
been reported by Rosas et al. and Douaud et al. [8, 30]. The
added value of our study lies not only in the large sample
size facilitating the further speciﬁcation of the premanifest
and manifest groups, but particularly in the fact that the
atrophy described takes into account whole-brain atrophy.
It should be noted that some caution is appropriate when
interpreting the ratio to whole-brain atrophy, as this method
does not necessarily imply that the volume reduction of a
certain structure has to be greater than the whole brain
atrophy to be of signiﬁcance in terms of clinical symptoms.
The clinical impact of atrophy of subcortical grey matter
is difﬁcult to assess as many brain structures are involved
in complex functionality. We have demonstrated that of the
subcortical grey matter structures, speciﬁcally volume
reductions of the accumbens nucleus, putamen and palli-
dum have the greatest inﬂuence on predicting the motor
disturbances in manifest HD, and perhaps surprisingly, the
impact of the caudate nucleus is minimal. The role of the
pallidum in motor function is underestimated and surpasses
the caudate nucleus and the thalamus. However, the puta-
men is the most important structure for this clinical
symptom. Our study shows that decreased global func-
tioning of manifest HD was mainly related to volume loss
of the hippocampus, putamen and pallidum. Cognitive and
motor deﬁciencies have been shown in a number of sepa-
rate studies, all examining only part of the deep grey matter
structures, to relate to volume reductions of the basal
ganglia, thalamus and frontal lobe [1, 4, 6, 7, 10, 14, 26,
33]. Within one small cohort examination of clinical
measures with the TFC was carried out by Rosas et al. who
provided evidence for an association between each separate
structure and the TFC in the manifest stage [30], which,
apart from some differences between studies, is largely
conﬁrmed by our study. All these studies show that there is
an association between volumes and clinical measures;
however, we hope that by examining all structures within
one large, well deﬁned cohort, we can provide evidence for
which structure has the most contribution (or at least the
strongest correlation) to global functioning and motor
disturbances.
TRACK-HD is a longitudinal observational biomarker
study aimed at providing essential methodology for the
assessment of therapeutic interventions. With respect to
this goal, we can add that the accumbens nucleus and
pallidum show similar biomarker potential in addition to
the well recognised structures putamen and caudate
nucleus. The hippocampus is also of importance as it has a
high correlation with clinical symptoms. The important
role of the caudate nucleus in the premanifest stage of the
disease seems to diminish after manifestation, as was also
suggested by the TRACK-HD baseline paper [39]. It is
possibly fair to say that at different disease stages different
structures play a role. A biomarker would ideally show
sensitivity across all disease stages and would reﬂect the
underlying pathologic processes. From this cross-sectional
analysis it is not possible to draw any deﬁnitive conclu-
sions; however, the putamen possibly shows the greatest
potential. Longitudinal evaluation has to be performed to
conﬁrm the putamen’s true potential. Furthermore we
would like to stress how taking whole brain atrophy into
account aids our interpretation of regional atrophy rates
and in this way their potential as biomarkers can be
assessed more effectively.
A limitation of our study could be the use of a relatively
new software package from FSL used for segmentation,
which has not speciﬁcally been validated in HD. Visual
inspection, however, did not reveal any signiﬁcant mis-
matches. The method applied gives structure segmentation
on an individual basis and can therefore be used to compare
groups. In contrast to this limitation several clear reasons
exist in favor of using FIRST—ﬁrst of all, compared to
manual segmentation the automated segmentation uses
voxel intensity in contrast to the sometimes difﬁcult visual
contrast differences, reducing a rater dependent bias. Sec-
ondly, this automated technique is suitable for implantation
on large datasets, whereas manual segmentation is labour
intensive and prone to human error.
In conclusion, we have demonstrated that atrophy of the
pallidum and the accumbens nucleus exists in the pre-
manifest stages of the disease and conﬁrmed the well
known atrophy of the caudate nucleus and putamen. Fur-
thermore, we have shown the important correlation of the
accumbens nucleus, putamen, pallidum and hippocampus
with clinical symptoms. The importance of the remaining
subcortical structures should be regarded when taking into
account that they show similar amounts of atrophy as the
brain as a whole. These ﬁndings have implications for
biomarker research, as several subcortical structures now
show great potential for use as a disease progression
measure.
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